Eagle Pharmaceuticals (EGRX) Misses Q4 EPS Views

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.07, $0.23 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $18.2 million versus the consensus estimate of $20.78 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM